Thiazolidinediones (pioglitazone and rosiglitazone) are PPAR-γ agonists that, administered to T2DM patients, may cause weight gain with a favorable shift in fat distribution from VAT to SAT [164]. This evidence concerns the gene PPARG and type 2 diabetes mellitus.